Phase II Single-arm, Single-center Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Tretinoin (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 17 Jan 2024 Status changed from not yet recruiting to recruiting.
- 29 Nov 2023 Planned End Date changed from 1 Oct 2026 to 1 Oct 2028.
- 29 Nov 2023 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2026.